Kevin Feeley Sells 317 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 317 shares of the business’s stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $93.99, for a total transaction of $29,794.83. Following the transaction, the chief financial officer directly owned 9,168 shares in the company, valued at approximately $861,700.32. The trade was a 3.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, December 16th, Kevin Feeley sold 3,855 shares of GeneDx stock. The stock was sold at an average price of $143.87, for a total transaction of $554,618.85.
• On Tuesday, December 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The shares were sold at an average price of $159.28, for a total transaction of $201,648.48.

GeneDx Stock Performance

GeneDx stock opened at $95.23 on Wednesday. The firm has a 50 day simple moving average of $131.03 and a 200-day simple moving average of $125.13. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of 1,058.11 and a beta of 2.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. GeneDx Holdings Corp. has a 1-year low of $55.17 and a 1-year high of $170.87.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Guggenheim restated a “buy” rating and issued a $170.00 target price (up previously from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Wall Street Zen raised GeneDx from a “hold” rating to a “buy” rating in a research report on Saturday. BTIG Research upped their target price on shares of GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Canaccord Genuity Group increased their target price on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Finally, Wells Fargo & Company set a $155.00 price target on shares of GeneDx and gave the company an “equal weight” rating in a research report on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and an average target price of $138.13.

More GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Analyst consensus remains favorable — the stock carries a “Moderate Buy” consensus and several firms have recently reaffirmed or raised price targets, which supports longer-term upside. Analyst Consensus
• Neutral Sentiment: Institutional ownership is sizable (~61.7%) with modest quarter-to-quarter adjustments by some funds; that large institutional base can dampen short-term volatility but also concentrates moves when sentiment shifts. Institutional & Insider Summary
• Neutral Sentiment: Reported short-interest data in the recent update is effectively zero/insignificant (likely a data anomaly), so short-covering dynamics are not a clear driver of today’s move. No clear short squeeze risk is indicated.
• Negative Sentiment: Multiple insider sales by senior executives: COO Bryan Dechairo sold 3,413 shares (~$339.7k) and CEO Katherine Stueland sold 1,653 shares (both late January transactions disclosed in SEC filings). Such clustered insider selling by C‑suite members can signal to the market a reduced near-term insider conviction. COO Form 4 CEO Form 4
• Negative Sentiment: CFO Kevin Feeley also sold shares (317 shares reported), adding to the pattern of insider sales and amplifying investor concern about executive liquidity events. CFO Sale
• Negative Sentiment: Technical picture is unfavorable: the share price sits well below the 50-day and 200-day moving averages cited in recent summaries, which can prompt momentum selling from traders using technical triggers. Price & Technicals

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp increased its stake in GeneDx by 664.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after buying an additional 186 shares during the period. Quarry LP boosted its position in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new position in shares of GeneDx in the third quarter worth $65,000. AlphaQuest LLC increased its position in shares of GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock worth $70,000 after acquiring an additional 594 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of GeneDx by 479.0% in the second quarter. Tower Research Capital LLC TRC now owns 1,818 shares of the company’s stock valued at $168,000 after acquiring an additional 1,504 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.